Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than
Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th
Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing
Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.
Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.